| VICI |
Report |
Q2 2026 AFFO per diluted share |
IN-LINE |
pred ~$0.62 vs. cons $0.62 |
HIGH |
| VICI |
Report |
Q2 2026 total revenue |
BEAT |
pred ~$1.055B vs. cons $1.040B |
MEDIUM |
| VICI |
Report |
Q2 2026 adjusted EBITDA |
IN-LINE |
pred ~$872M vs. cons $865M |
MEDIUM |
| VICI |
Guide |
AFFO per diluted share |
BETTER |
guide ~$2.465 midpoint vs. cons $2.46 (FY2026) |
MEDIUM |
| VICI |
Guide |
AFFO attributable to common stockholders |
BETTER |
guide ~$2.690B midpoint vs. cons $2.683B (FY2026) |
MEDIUM |
| VICI |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.4% |
— |
MEDIUM |
| VICI |
Return |
5-day cumulative residual |
+0.6% (FADE) |
Day-1 residual +1.4% fades to a +0.6% five-day residual because the modest revenue beat and small FY2026 guidance increase support the stock initially, but limited per-share upside versus the $2.46 consensus—after acquisition-related dilution and refinancing costs—leaves out-period estimate revisions small. |
MEDIUM |